Intranasal fusion inhibitory lipopeptide prevents direct-contact SARS-CoV-2 transmission in ferrets-Reference-Cited by-同舟云学术

Intranasal fusion inhibitory lipopeptide prevents direct-contact SARS-CoV-2 transmission in ferrets

Published:2021-03-26 Issue:6536 Volume:371 Page:1379-1382
ISSN:0036-8075
Container-title:Science
language:en
Short-container-title:Science

Author:

de Vries Rory D.¹^ORCID,Schmitz Katharina S.¹^ORCID,Bovier Francesca T.²³⁴^ORCID,Predella Camilla²⁵^ORCID,Khao Jonathan⁶^ORCID,Noack Danny¹^ORCID,Haagmans Bart L.¹^ORCID,Herfst Sander¹^ORCID,Stearns Kyle N.²³⁷^ORCID,Drew-Bear Jennifer²³,Biswas Sudipta⁸^ORCID,Rockx Barry¹^ORCID,McGill Gaël⁶⁹^ORCID,Dorrello N. Valerio²^ORCID,Gellman Samuel H.¹⁰^ORCID,Alabi Christopher A.⁸^ORCID,de Swart Rik L.¹^ORCID,Moscona Anne²³⁷¹¹^ORCID,Porotto Matteo²³⁴^ORCID

Affiliation:

1. Department of Viroscience, Erasmus MC, Rotterdam, Netherlands.

2. Department of Pediatrics, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA.

3. Center for Host–Pathogen Interaction, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA.

4. Department of Experimental Medicine, University of Campania “Luigi Vanvitelli,” Caserta, Italy.

5. Department of Biomedical Engineering, Politecnico di Milano, Milan, Italy.

6. Digizyme Inc., Brookline, MA, USA.

7. Department of Physiology and Cellular Biophysics, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA.

8. Robert Frederick Smith School of Chemical and Biomolecular Engineering, Cornell University, Ithaca, NY, USA.

9. Center for Molecular and Cellular Dynamics, Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA.

10. Department of Chemistry, University of Wisconsin–Madison, Madison, WI, USA.

11. Department of Microbiology and Immunology, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA.

Abstract

Halting transmission The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) glycoprotein binds to host cells and initiates membrane fusion and cell infection. This stage in the virus life history is currently a target for drug inhibition. De Vries et al. designed highly stable lipoprotein fusion inhibitors complementary to a conserved repeat in the C terminus of S that integrate into host cell membranes and inhibit conformational changes in S necessary for membrane fusion. The authors tested the performance of the lipoproteins as a preexposure prophylactic in a ferret-to-ferret transmission study. Intranasal administration of the peptide 2 days before cohousing with an infected ferret for 24 hours completely protected animals in contact from infection and showed efficacy against mutant viruses. Because ferrets do not get sick from SARS-CoV-2, disease prevention could not be tested in this model. Science , this issue p. 1379

Funder

National Institutes of Health

Irving Medical Center, Columbia University

Academia Militar

Harrington Discovery Institute

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

Reference33 articles.

1. Structure, Function, and Evolution of Coronavirus Spike Proteins

2. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor